The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Inhibitors in the Swedish population with severe haemophilia A and B : A 20-year survey

På svenska

Author

  • Karin Knobe
  • Elsy Sjörin
  • Lilian Tengborn
  • P Petrini
  • Rolf Ljung

Summary, in English

Aim: To survey the entire population (n = 116) afflicted with severe haemophilia A or B born in Sweden over a 20-y period (1980-1999), and to examine the epidemiological, genetic and clinical aspects of development of inhibitors to factors VIII and IX (FVIII/FIX). Methods: One hundred of the subjects had haemophilia A and 16 had haemophilia B. All of these subjects had received prophylactic treatment and had a check-up of inhibitor status at least twice a year. Sixty-one were born between 1980 and 1989 and 55 between 1990 and 1999. Results: Nineteen percent (19/100) of those with haemophilia A and 37% (6/16) with haemophilia B developed inhibitors at 12-18 mo of age, after exposure to FVIII/FIX concentrates for an average of 14d in the case of haemophilia A and 16 d in haemophilia B. All patients with inhibitors carried mutations that impaired protein synthesis. The high incidence of FIX inhibitors may have been due to the large number of complete deletions (13%) in the Swedish haemophilia B population. Patients with haemophilia A showed no significant increase (p = 0.65) in incidence of inhibitors (n = 10/48, total incidence 21%) in the 1990s, when they were treated mainly with recombinant products, as compared to the 1980s (n=9/52, 17%) when they received intermediate/high-purity plasma-derived concentrates. Conclusion: Our population-based study verifies that genotype has a general impact on the incidence of FVIII/FIX inhibitors, and that recombinant FIII/FIX concentrates are not a predisposing factor for inhibitor development.

Publishing year

2002

Language

English

Pages

910-914

Publication/Series

Acta Pædiatrica

Volume

91

Issue

8

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Pediatrics

Keywords

  • Factor IX
  • Factor VIII
  • Haemophilia A
  • Haemophilia B
  • Inhibitor

Status

Published

ISBN/ISSN/Other

  • ISSN: 1651-2227